DxTerity
DxTerity is a California-based molecular diagnostics company that runs a CAP-accredited, CLIA-certified laboratory offering RNA-based genomic tests and at-home blood collection devices for autoimmune disease management, serving physicians, autoimmune patients, and biopharmaceutical partners developing companion diagnostics.
- Company typePrivate
- Founded2006
- HeadquartersRancho Dominguez, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What DxTerity does
DxTerity Diagnostics Inc. is a Torrance, California-based molecular diagnostics company founded in 2006 that develops RNA-based precision diagnostic tests for autoimmune diseases. Its core technology is the proprietary DxDirect platform, which uses non-enzymatic Chemical Ligation Probe Assay (CLPA) chemistry to convert mRNA targets into uniquely-sized ligation products detected by PCR amplification and capillary electrophoresis on a ThermoFisher 3500Dx instrument — a workflow that bypasses sample purification and supports up to 1,500 samples per day per system with a 6-hour sample-to-answer turnaround. Its companion DxCollect product line (MicroCollection Device and Blood Collection Tube) provides 14-day ambient-temperature RNA stabilization, enabling at-home fingerstick self-collection and standard mail shipping without cold-chain logistics.
The company's commercial test portfolio includes the Type 1 Interferon (IFN-1) focused assay, which stratifies systemic lupus erythematosus (SLE) patients for likely response to anifrolumab, and the Modular Immune Profile (MIP) targeted panel covering gene signatures for IFN-1, B-cells, T-cells, neutrophils, and plasmablasts for use in lupus, rheumatoid arthritis, and Sjögren's syndrome. The platform is operated from a CAP-accredited, CLIA-certified, ISO 13485:2016-compliant laboratory and is approved for distribution across all 50 US states plus the European Union (via CE Mark for DxCollect). Note that these tests are LDTs and have not been cleared or approved by the FDA, and require a physician order.
DxTerity generates revenue through three streams: per-test laboratory diagnostic services ordered by physicians (including via at-home DxCollect kits), sale of DxCollect collection devices, and custom development services — Clinical Trial Assays (CTAs) and Companion Diagnostics (CDx) — for biopharmaceutical partners engaged in autoimmune drug development. Customer segments include rheumatology practices and academic medical centers ordering tests, biopharmaceutical companies (including multiple top-10 global firms) using DxCollect for clinical trial patient stratification, and nonprofit research organizations such as the Lupus Research Alliance and Lupus Therapeutics. Distribution combines a physician-ordered domestic model, at-home self-collection, and direct B2B enterprise partnerships with pharma.
DxTerity firmographics
Firmographics- Name
- DxTerity
- Legal name
- DxTerity Diagnostics Inc.
- Website
- https://dxterity.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DxTerity is a California-based molecular diagnostics company that runs a CAP-accredited, CLIA-certified laboratory offering RNA-based genomic tests and at-home blood collection devices for autoimmune disease management, serving physicians, autoimmune patients, and biopharmaceutical partners developing companion diagnostics.
- Ownership category
- akta.pro rank
DxTerity industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)
- akta.pro secondary industries
- Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Autoimmune & Allergy Diagnostics (HLAAALAK)
Keywords
Where DxTerity is headquartered
LocationHeadquarters
- HQ city
- Rancho Dominguez
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
DxTerity business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Laboratory Testing Services: RNA-based diagnostic testing services performed in DxTerity's CAP-accredited, CLIA-certified laboratory. Tests ordered by physicians for patients with autoimmune diseases. Revenue generated per test with 7 business day turnaround time available.
- DxCollect Products: Sale of blood collection products including DxCollect MicroCollection Device (MCD) and Blood Collection Tube (BCT). Products enable fingerstick self-collection with 14-day RNA stabilization at room temperature for shipping.
- Development Services: Custom diagnostic development services for pharmaceutical companies including Clinical Trial Assays (CTA) and Companion Diagnostics (CDx). Services span from concept through commercialization including assay design, regulatory guidance, and manufacturing support.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Laboratory testing services - physician-ordered tests |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
DxTerity product offering
Product offeringCore offering
DxTerity operates a CAP-accredited, CLIA-certified clinical laboratory that develops and delivers RNA-powered precision diagnostics for autoimmune diseases. The portfolio includes physician-ordered tests (Type 1 Interferon and Modular Immune Profile), proprietary at-home blood collection devices (DxCollect MCD and BCT) with 14-day ambient RNA stabilization, a CLPA-based testing platform (DxDirect), and custom Clinical Trial Assay and Companion Diagnostic development services for pharmaceutical partners.
Product overview
DxTerity offers a unified portfolio of RNA-based diagnostic products organized around two core platforms: DxCollect (blood collection devices) and DxDirect (testing platform). The DxCollect product line includes the MicroCollection Device (MCD) for fingerstick self-collection and the Blood Collection Tube (BCT) for venipuncture, both providing 14-day ambient RNA stabilization. The DxDirect platform enables high-throughput RNA testing without sample purification. Testing products include the Type 1 Interferon (IFN-1) focused assay and the Modular Immune Profile (MIP) targeted panel assay. The company also provides Development Services for pharmaceutical partners including assay design, clinical studies, regulatory guidance, and manufacturing for companion diagnostics.
Differentiator
Problem solved
Functional benefit
Brands
- DxDirect: CLPA-based testing platform for direct-from-blood and tissue RNA testing using non-enzymatic chemical ligation technology.
- DxCollect
Products and services
- Type 1 Interferon (IFN-1) Test Focused assay measuring interferon pathway activity to identify SLE patients more likely to experience moderate to severe disease, helping identify candidates for targeted therapies such as anifrolumab. Requires a physician order.
- Modular Immune Profile (MIP) Test Targeted panel assay providing broad immune system analysis including gene signatures for IFN-1, B-cells, T-cells, plasmablasts, neutrophils, and other immune pathways to characterize autoimmune disease and therapeutic response.
- DxCollect MCD (MicroCollection Device) Finger stick self-collection device enabling blood draw with 14-day RNA stabilization at room temperature, allowing ambient shipping for DNA and RNA genomic testing without dry ice.
- DxCollect BCT (Blood Collection Tube) Evacuated blood draw tube (1 mL draw) with 14-day ambient RNA stabilization, compatible with standard venipuncture workflows.
- DxDirect Kits RNA-based testing kits utilizing a unique analytical process that eliminates sample purification and enables high-throughput processing (up to 1500 samples per day per system, 6 hour sample-to-answer).
- Development Services Custom diagnostic development services for pharmaceutical companies including assay design, analytical validation, clinical studies, regulatory guidance, manufacturing, and data management for Clinical Trial Assays (CTA) and Companion Diagnostics (CDx).
Quantifiable outcome
- Over 1 million tests processed
- +3 more outcomes
Companies that use DxTerity
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
DxTerity technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
DxTerity partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship and core.
- Lupus Research AllianceflagshipStrategic partnership for the 5-year Lupus Landmark Study - a prospective longitudinal study targeting enrollment of up to 3,500 adults diagnosed with systemic lupus erythematosus (SLE). DxTerity provides testing using its Modular Immune Profile (MIP) assay including gene signatures for IFN-1, B-cells, T-cells, and other immune pathways. The study aims to provide real-world data and clinical samples to evaluate therapy effectiveness and power precision medicine development for SLE.
- Lupus TherapeuticsflagshipClinical research affiliate of Lupus Research Alliance collaborating on the Lupus Landmark Study. Partnership enables patient-centric, collaborative research resource (Lupus Nexus) for accelerating personalized treatments in lupus through large-scale genomic monitoring.
- Pharmaceutical Companies (Multiple)coreDxCollect device deployed for patient stratification and monitoring in large-scale, direct-to-patient clinical studies. Multiple pharmaceutical companies use DxCollect for RNA preservation in clinical trials. Trusted by top ten global bio-pharmaceutical companies according to company statements.
- Biotech and Pharmaceutical Industry ParticipantscoreDxTerity has partnered with biotech and pharmaceutical industry participants in autoimmune to identify emerging biomarkers in therapeutic targeting. Targeted panel tests seek to establish claims across diagnostic, prognostic, and theranostic testing aims. Active in clinical trials with ongoing regulatory filings to establish standardized testing in clinical practice.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
DxTerity competitors and assessment
Company assessmentMarket position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
DxTerity social profiles
Digital presenceDxTerity compliance and trust
Trust signalCompliance11 records
DxTerity financial estimates
Financial estimateRevenue estimate
Valuation estimate
DxTerity leadership team
Management profileNumber of profiles
Profiles1 record
DxTerity funding detail
Funding detailFunding overview
Funding rounds5 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DxTerity M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DxTerity
What does DxTerity do?
DxTerity operates a CAP-accredited, CLIA-certified clinical laboratory that develops and delivers RNA-powered precision diagnostics for autoimmune diseases. The portfolio includes physician-ordered tests (Type 1 Interferon and Modular Immune Profile), proprietary at-home blood collection devices (DxCollect MCD and BCT) with 14-day ambient RNA stabilization, a CLPA-based testing platform (DxDirect), and custom Clinical Trial Assay and Companion Diagnostic development services for pharmaceutical partners.
Is DxTerity a public or private company?
DxTerity is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was DxTerity founded?
DxTerity was founded in 2006. It employs 11 to 50 people.
Where is DxTerity based?
DxTerity is headquartered in Rancho Dominguez, United States, in the North America region.
How does DxTerity make money?
Three revenue lines are on record. Laboratory Testing Services are the primary driver. The others are dxCollect Products and development Services.
Does DxTerity have an API?
No public API is recorded for DxTerity.
What industry is DxTerity in?
DxTerity's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators), with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 621511 and its SIC code is 2835.